Confronting the Challenges of Osteoporosis: New Approaches and Emerging Treatments- Enduring

This activity is supported by an educational grant from Amgen Inc.



Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with bone and calcium disorders.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Summarize current clinical challenges in the diagnosis and management of osteoporosis and discuss common barriers to success
  • Apply current guidelines and state of care methods when assessing and treating patients at risk for low trauma fractures or living with osteoporosis
  • Discuss the mechanism of action, benefits, and limitations of emerging osteoporosis therapies, and recognize the potential impact of current trials on practice

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Bone and Calciotropic Hormones
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation
Course opens: 
Course expires: 

Program Director

Michael R. McClung, MD 
Director, Oregon Osteoporosis Center
Portland, OR
João Lindolfo Borges, MD
Professor of Endocrinology
Universidade Catolica de Brasilia
Brasilia, Brazil
David Kendler, MD, FRCPC
Professor of Medicine (Endocrinology)
University of British Columbia
Vancouver, Canada
Clifford J. Rosen, MD
Director, Maine Medical Center Research Institute
Scarborough, ME




The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity: 
Michael R. McClung, MD: Consultant, Radius Health, Inc., Amgen; Speaker, Amgen
David Kendler, MD, FRCPC: Research Support, Amgen; Speaker, Amgen, Eli Lilly & Company, GlaxoSmithKline; Consultant, Eli Lilly & Company; Investigator, Eli Lilly & Company, Astra Zeneca; Advisory Group Member, Pfizer, Inc.
The faculty reported the no relevant financial relationship: Clifford J. Rosen, MD, João Lindolfo Borges, MD
The following SPC member who reviewed content for this activity reported the relevant financial relationships: 
E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, Dexcom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Alan Kelly, MD: Speaker, Eli Lilly
Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships: Connie Newman, MD, 
Amy Rothberg, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation